M&A Deal Summary |
|
---|---|
Date | 2024-07-29 |
Target | Ironshore Therapeutics |
Sector | Life Science |
Buyer(s) | Collegium Pharmaceutical |
Deal Type | Add-on Acquisition |
Deal Value | 525M USD |
Advisor(s) | Centerview Partners (Financial) Goodwin Procter (Legal) |
SEARCH BY
Try For Free 7-Day Free Trial
Category | Company |
---|---|
Founded | 2002 |
Sector | Life Science |
Employees | 197 |
Revenue | 567M USD (2023) |
Collegium Pharmaceutical offers specialty pharmaceutical services by developing and planning to commercialize next-generation, abuse-deterrent products for patients suffering from chronic pain. Collegium Pharmaceutical was founded in 2002 and is based in Stoughton, Massachusetts.
DEAL STATS | # |
---|---|
Overall | 3 of 3 |
Sector (Life Science) | 3 of 3 |
Type (Add-on Acquisition) | 2 of 2 |
State (North Carolina) | 2 of 2 |
Country (United States) | 3 of 3 |
Year (2024) | 1 of 1 |
Size (of disclosed) | 2 of 3 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2022-02-14 |
BioDelivery
Raleigh, North Carolina, United States BioDelivery is a commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions. BDSI has built a portfolio of differentiated pain and neurology products and leverages its experienced sales and marketing organization to educate prescribers on their unique features. BioDelivery was formed in 1997 and is based in Raleigh, North Carolina. |
Buy | $604M |